<DOC>
	<DOCNO>NCT02584309</DOCNO>
	<brief_summary>The purpose research study look whether give drug call dexrazoxane plus olaratumab standard care doxorubicin affect progression disease . Dexrazoxane often give time doxorubicin help reduce incidence severity disease heart muscle ( cause doxorubicin ) .</brief_summary>
	<brief_title>Doxorubicin With Upfront Dexrazoxane Plus Olaratumab Treatment Advanced Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<mesh_term>Hemangiosarcoma</mesh_term>
	<mesh_term>Fibrosarcoma</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neurofibrosarcoma</mesh_term>
	<mesh_term>Histiocytoma , Malignant Fibrous</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>Histologically confirm grade 2 3 soft tissue sarcoma unresectable metastatic . Surgery primary metastatic disease chemotherapy follow response allow . Patients follow tumor type eligible : Undifferentiated pleomorphic sarcoma Leiomyosarcoma Malignant fibrous histiocytoma Liposarcoma ( myxoid/round cell , pleomorphic dedifferentiate ) Synovial sarcoma Myxofibrosarcoma Angiosarcoma Fibrosarcoma Malignant peripheral nerve sheath tumor Epithelioid sarcoma Unclassified highgrade sarcoma ( otherwise specify ) Measurable disease accord RECIST 1.1 ; , measurable disease define lesion accurately measure least one dimension ( long diameter record ) ≥ 10 mm CT scan , ≥ 20 mm chest xray , ≥ 10 mm caliper clinical exam . Planning initiate treatment doxorubicin ( start dose 75 mg/m2 ) olaratumab ( start dose 15 mg/kg ) routine care . Prior adjuvant chemotherapy gemcitabine and/or docetaxel/paclitaxel allow . At least 18 year age . ECOG performance status 0 1 Adequate organ function define : Leukocytes ≥ 3,000/mcL Absolute neutrophil count ≥ 1,500/mcl Platelets ≥ 100,000/mcl Total bilirubin ≤ 1.5 x IULN AST ( SGOT ) /ALT ( SGPT ) ≤ 3.0 x IULN Creatinine ≤ IULN OR Creatinine clearance ≥ 60 mL/min/1.73 m^2 patient creatinine level institutional normal Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Able understand willing sign IRB approve write informed consent document ( legally authorize representative , applicable ) . Myocardial infarction within past 12 month , stable unstable angina . Systolic heart failure define leave ventricular ejection fraction ≤ 45 % . Symptomatic valvular heart disease . Prior chemotherapy advance metastatic disease . Known brain metastasis . Prior second primary malignancy within last two year ( except carcinoma situ cervix , nonmetastatic prostate cancer , basal cell squamous cell carcinoma skin treat local resection ; prior adjuvant androgen deprivation therapy case prostate cancer permit , current adjuvant androgen deprivation therapy ) . Currently receive investigational agent . A history allergic reaction attribute compound similar chemical biologic composition dexrazoxane agent use study . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , psychiatric illness/social situation would limit compliance study requirement . Pregnant and/or breastfeeding . Patient must negative pregnancy test within 14 day study entry . Known HIVpositivity combination antiretroviral therapy potential pharmacokinetic interaction dexrazoxane . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate . Prior treatment anthracyclines .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>